Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 503 matching drugs for SLC29A2 — including drugs targeting any of its 88 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells SLC29A2 Direct 2
ethanol, enoxaparin SLC29A2 Direct 1
sunitinib FLT1 SSL via FLT1 yes 5
sunitinib KDR SSL via KDR yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FLT1 SSL via FLT1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KDR SSL via KDR 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FLT1 SSL via FLT1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KDR SSL via KDR 4
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis PDPK1 SSL via PDPK1 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine KDR SSL via KDR 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine RRM1 SSL via RRM1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CSK SSL via CSK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDR SSL via KDR 3
gemcitabine RRM1 SSL via RRM1 yes 3
pembrolizumab, belzutifan, lenvatinib FLT1 SSL via FLT1 3
pembrolizumab, belzutifan, lenvatinib KDR SSL via KDR 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab RRM1 SSL via RRM1 3
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin RRM1 SSL via RRM1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FLT1 SSL via FLT1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan KDR SSL via KDR 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine RRM1 SSL via RRM1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 FLT1 SSL via FLT1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 KDR SSL via KDR 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CSK SSL via CSK 2
cabozantinib KDR SSL via KDR yes 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib KDR SSL via KDR 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PDPK1 SSL via PDPK1 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab RRM1 SSL via RRM1 2
cpt- 11, cisplatin, celecoxib, radiation, surgery PDPK1 SSL via PDPK1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib KDR SSL via KDR 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FLT1 SSL via FLT1 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KDR SSL via KDR 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine RRM1 SSL via RRM1 2
lenvatinib, pembrolizumab FLT1 SSL via FLT1 2
lenvatinib, pembrolizumab KDR SSL via KDR 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FLT1 SSL via FLT1 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KDR SSL via KDR 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab RRM1 SSL via RRM1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed RRM1 SSL via RRM1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FLT1 SSL via FLT1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a KDR SSL via KDR 2
nab-paclitaxel, gemcitabine RRM1 SSL via RRM1 2
nintedanib FLT1 SSL via FLT1 yes 2
nintedanib KDR SSL via KDR yes 2
nintedanib, pembrolizumab FLT1 SSL via FLT1 2
nintedanib, pembrolizumab KDR SSL via KDR 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu RRM1 SSL via RRM1 2
pazopanib FLT1 SSL via FLT1 yes 2
pazopanib KDR SSL via KDR yes 2
pembrolizumab, lenvatinib FLT1 SSL via FLT1 2
pembrolizumab, lenvatinib KDR SSL via KDR 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FLT1 SSL via FLT1 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu KDR SSL via KDR 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FLT1 SSL via FLT1 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin KDR SSL via KDR 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin RRM1 SSL via RRM1 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FLT1 SSL via FLT1 2
ramucirumab KDR SSL via KDR yes 2
ramucirumab, paclitaxel KDR SSL via KDR 2
regorafenib FLT1 SSL via FLT1 yes 2
regorafenib KDR SSL via KDR yes 2
regorafenib, laboratory biomarker analysis FLT1 SSL via FLT1 2
regorafenib, laboratory biomarker analysis KDR SSL via KDR 2
sorafenib, administered orally, ct/mri FLT1 SSL via FLT1 2
sorafenib, administered orally, ct/mri KDR SSL via KDR 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel RRM1 SSL via RRM1 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy KDR SSL via KDR 2
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) KDR SSL via KDR 1
7-hydroxystaurosporine, fluorouracil PDPK1 SSL via PDPK1 1
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis PDPK1 SSL via PDPK1 1
9-ing-41, retifanlimab, gemcitabine, abraxane RRM1 SSL via RRM1 1
abemaciclib, ly3023414, gemcitabine, capecitabine RRM1 SSL via RRM1 1
abraxane (nab-paclitaxel), gemcitabine RRM1 SSL via RRM1 1
adct-601, gemcitabine RRM1 SSL via RRM1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CSK SSL via CSK 1
ag-013736, gemcitabine, gemcitabine, placebo RRM1 SSL via RRM1 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel RRM1 SSL via RRM1 1
agent-797, botensilimab, balstilimab, ramucirumab, paclitaxel KDR SSL via KDR 1
ags-1c4d4, gemcitabine RRM1 SSL via RRM1 1
ak104, ak104, gemcitabine, nab-paclitaxel RRM1 SSL via RRM1 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine RRM1 SSL via RRM1 1
albumin-bound paclitaxel (abi-007), gemcitabine RRM1 SSL via RRM1 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes RRM1 SSL via RRM1 1
alisertib AURKA SSL via AURKA 1
alisertib, gemcitabine AURKA SSL via AURKA 1
alisertib, gemcitabine RRM1 SSL via RRM1 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox RRM1 SSL via RRM1 1
amg 479, placebo, amg 479, gemcitabine RRM1 SSL via RRM1 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel RRM1 SSL via RRM1 1
apg-1387 for injection, gemcitabine, nab paclitaxel RRM1 SSL via RRM1 1
apx005m, nivolumab, nab-paclitaxel, gemcitabine RRM1 SSL via RRM1 1
arq 197, gemcitabine RRM1 SSL via RRM1 1
ascorbate, nab paclitaxel, gemcitabine RRM1 SSL via RRM1 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine RRM1 SSL via RRM1 1
atezolizumab, cabozantinib KDR SSL via KDR 1
atezolizumab, tivozanib FLT1 SSL via FLT1 1
atezolizumab, tivozanib KDR SSL via KDR 1
atra, gemcitabine, nab-paclitaxel RRM1 SSL via RRM1 1
autologous mesothelin-specific tcr-t cells, cyclophosphamide, fludarabine, bendamustine RRM1 SSL via RRM1 1
avastin (bevacizumab), gemcitabine, radiation therapy RRM1 SSL via RRM1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.